Premature (Early) Ejaculation
Conditions
Keywords
premature ejaculation, sexual function, ejaculatory profile, latency time
Brief summary
Both Silodosin 4 mg and Dapoxetine 60 mg significantly improved IELT and sexual function scores in primary PE patients. However, Silodosin exhibited a more favorable tolerability profile with fewer side effects, making it a safer, clinically effective alternative.
Detailed description
Dapoxetine 60 mg, the initial FDA-approved on-demand treatment for PE, which is a selective serotonin reuptake inhibitor (SSRI) . However, Silodosin 4 mg, an α1-adrenoceptor antagonist, has emerged as a promising alternative, particularly for patients dissatisfied with Dapoxetine . This investigation is designed to evaluate the efficacy and tolerability of Silodosin 4mg and Dapoxetine 60mg in the treatment of primary premature ejaculation.
Interventions
DRUGsildosin 4mg
ondemand sildosin 4mg
DRUGdapoxetine 60mg
ondemand dapoxetine 60mg
Sponsors
Benha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
25 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Heterosexual male * Sexually active * Aged 25 to 65 years old. * Primary premature ejaculation (IELT \< 1 minute) * They had experienced PE for a minimum of 6 months
Exclusion criteria
* Patients with a history of diabetes or * Uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg) was precluded from the study. * Anatomic abnormalities of the penis or genital region, * Erectile dysfunction, * Chronic prostatitis, * Psychological disorder * Patients on anti-psychotic drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intravaginal ejaculatory Latency time | 2 months | changes in latency time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| side effects | 2 months | any side effects were recorded |
Countries
Egypt
Outcome results
None listed